CerRx, Inc.   Report issue

For profit Phase 2
Founded: Lubbock TX United States (2008)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02495415
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

n-(4-hydroxyphenyl)all-trans retinamide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1